Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Ayvakit Sprinkle

(Avutometinib)

Phase 2Small molecule

MMemorial Sloan Kettering Cancer Center

This medication combines two drugs that block abnormal proteins in cancer cells, helping to stop or slow the growth and spread of a specific type of ovarian cancer.[1] Ayvakit Sprinkle is currently being investigated across 10 indications[3], with its most advanced program in Phase 2.[1]

Ayvakit Sprinkle is one of 262 small molecule programs targeting Cutaneous Melanoma. It is currently in Phase 2.

10

Indications

18

Total Trials

16

Active Trials

261

Competitors

Pipeline

Status by Indication[3][1]

Indication

Cutaneous MelanomaRecruiting

Pancreatic AdenocarcinomaNot yet recruiting

Non-Small Cell Lung CancerCompleted

Pancreatic CancerNot yet recruiting

Ovarian CancerActive, not recruiting

Gastric CancerRecruiting

GlioblastomaActive, not recruiting

Low Grade Ovarian Serous AdenocarcinomaNot yet recruiting

MGMT-Unmethylated GlioblastomaNot yet recruiting

AvutometinibRecruiting

Cutaneous MelanomaPhase 2

Recruiting

Pancreatic AdenocarcinomaPhase 2

Not yet recruiting

Non-Small Cell Lung CancerPhase 2

Completed

Pancreatic CancerPreclinical

Not yet recruiting

Ovarian CancerPhase 2

Active, not recruiting

Gastric CancerPhase 2

Recruiting

GlioblastomaPhase 1

Active, not recruiting

Low Grade Ovarian Serous AdenocarcinomaPhase 2

Not yet recruiting

MGMT-Unmethylated GlioblastomaPhase 1

Not yet recruiting

AvutometinibPhase 2

Recruiting

Competition

Competitive Landscape

414 competitors in Non-Small Cell Lung Cancer

#DrugCompanyPhaseTrials

Femara

AK104

Ayvakit Sprinkle

MMemorial Sloan Kettering Cancer Center

Sitravatinib

MMirati Therapeutics Inc.

Remeron

OOrganon and Co

Aqupla

Jiangsu Simcere Pharmaceutical Co., Ltd.

Ftorafur

TThe First Affiliated Hospital with Nanjing Medical University

Vibramycin

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Treatment

PD-1 Inhibitors

BBioNTech US Inc.

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 2Active, not recruiting

Ovarian Cancer

NCT04625270

Q1 2027

Phase 2Active, not recruiting

Gynecologic Cancer

NCT05787561

Q2 2027

Phase 2Recruiting

Low-Grade Serous Ovarian Cancer

NCT06394804

Q3 2027

Phase 2Recruiting

Thyroid Cancer

NCT06007924

Clinical

Trials by Indication[1]

Non-Small Cell Lung Cancer2 trials

A Study of Avutometinib (VS-6766) + Defactinib in Recurrent KRAS G12V, Other KRAS and BRAF Non-Small Cell Lung Cancer

Completed·VVerastem, Inc.·Phase 2·NCT04620330·90 enrolled

Defactinib, Avutometinib and Nivolumab for the Treatment of Anti-PD1 Refractory LKB1-Mutant Advanced Non-Small Cell Lung Cancer

Recruiting·EEmory University·Phase 2·NCT06495125·50 enrolled

Avutometinib2 trials

5G-RUBY: Avutometinib and Defactinib in Malignant Brain Tumours

Recruiting·IInstitute of Cancer Research, United Kingdom·Phase 1/2·NCT06630260·182 enrolled

Phase Ib Study of Avutometinib, Defactinib, and Everolimus in RAS Pathway Mutant Endometrial Cancer

Recruiting·MM.D. Anderson Cancer Center·Phase 1·NCT07318324·31 enrolled

Low-grade Serous Ovarian Cancer2 trials

A Phase 3, Randomized, Open-Label Study of Combination Therapy With Avutometinib Plus Defactinib Versus Investigator's Choice of Treatment in Patients With Recurrent Low-Grade Serous Ovarian Cancer (LGSOC) (RAMP 301)

Recruiting·VVerastem, Inc.·Phase 3·NCT06072781·270 enrolled

Combination Targeted and Hormonal treAtMEnt of Low-gradE Serous Ovarian Cancer in the upfroNt Setting

Recruiting·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT06394804·20 enrolled

Cutaneous Melanoma1 trial

Defactinib and Avutometinib, With or Without Encorafenib, for the Treatment of Patients With Brain Metastases From Cutaneous Melanoma

Recruiting·UUniversity of Utah·Phase 1/2·NCT06194929·33 enrolled

Pancreatic Adenocarcinoma1 trial

Stereotactic Body Radiotherapy Plus FAK and RAF/MEK Inhibition in Advanced Pancreatic Adenocarcinoma

Not yet recruiting·WWashington University School of Medicine·Phase 2·NCT07126158·36 enrolled

10 more indications

Ovarian Cancer1 trial

A Study of Avutometinib (VS-6766) v. Avutometinib (VS-6766) + Defactinib in Recurrent Low-Grade Serous Ovarian Cancer With and Without a KRAS Mutation

Active, not recruiting·VVerastem, Inc.·Phase 2·NCT04625270·225 enrolled

Gastric Cancer1 trial

Avutometinib and Defactinib in Diffuse Gastric Cancer

Recruiting·—·Phase 2·NCT06487221·27 enrolled

Glioblastoma1 trial

Identification of Treatment Concentrations of Defactinib or VS-6766 for the Treatment of Patients With Glioblastoma

Active, not recruiting·EEmory University·Phase 1·NCT05798507·14 enrolled

Refractory Cancer1 trial

\Multi-Center Phase I Study of Avutometinib (VS-6766), a RAF/MEK Clamp in Combination With Defactinib, a FAK Inhibitor, in Pediatric Patients With Refractory or Recurrent Solid Tumors Harboring Activating MAPK Pathway or NF2 Alterations

Completed·MMemorial Sloan Kettering Cancer Center·Phase 1·NCT06104488·3 enrolled

Thyroid Cancer1 trial

Phase II of Avutometinib (VS-6766) and Defactinib In RAF Dimer-Driven RAI-Refractory Differentiated and Anaplastic Thyroid Cancer Patients

Recruiting·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT06007924·30 enrolled

Gynecologic Cancer1 trial

Single Arm Phase II Study of Avutometinib (VS-6766) and Defactinib in Advanced or Recurrent Mesonephric Gynecologic Cancer

Active, not recruiting·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT05787561·40 enrolled

Advanced Colorectal Cancer1 trial

Open-label Phase 2 Study of Avutometinib (RAF/MEK Clamp) in Combination With Defactinib (FAK Inhibitor) and Cetuximab in Patients With Unresectable, Anti-EGFR-Refractory Advanced Colorectal Cancer

Recruiting·MM.D. Anderson Cancer Center·Phase 2·NCT06369259·33 enrolled

Pancreatic Cancer1 trial

Neoadjuvant Avutometinib/Defactinib and mFOLFIRINOX Combination Therapy in Pancreatic Adenocarcinoma: A Phase IB/II Safety and Efficacy Study

Not yet recruiting·UUniversity of Virginia·Preclinical·NCT07824960·31 enrolled

MGMT-Unmethylated Glioblastoma1 trial

Safety and Feasibility of First-line Avutometinib and Defactinib in Patients With Newly Diagnosed High-grade Gliomas

Not yet recruiting·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 1·NCT07778602·22 enrolled

Low Grade Ovarian Serous Adenocarcinoma1 trial

Open-Label Extension Study to Provide Continued Access to Avutometinib in Combination With Defactinib in Patients With Recurrent Low-Grade Serous Ovarian Cancer (LGSOC)

Not yet recruiting·VVerastem, Inc.·Phase 2·NCT07747506·2 enrolled

Sources

References

[1]
ClinicalTrials.gov — 18 trial records for Avutometinib. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Avutometinib compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Avutometinib. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Memorial Sloan Kettering Cancer Center company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: MMemorial Sloan Kettering Cancer Center

Related News